BiotechTubeBiotechTube
Home/Pipeline/APG279 (Zumilokibart + APG990)

APG279 (Zumilokibart + APG990)

Moderate-to-Severe Atopic Dermatitis

Phase 1In-progress

Key Facts

Indication
Moderate-to-Severe Atopic Dermatitis
Phase
Phase 1
Status
In-progress
Company
Apogee Therapeutics

About Apogee Therapeutics

Founded in 2022, Apogee Therapeutics aims to reshape the standard of care for inflammatory and immune diseases by developing potentially best-in-class biologics with optimized dosing intervals. Its pipeline includes monotherapies and rational combinations targeting validated pathways like IL-13, OX40L, and TSLP across dermatological, respiratory, and gastroenterological conditions. The company is publicly traded (NASDAQ: APGE) and is advancing multiple programs with key clinical readouts expected in 2026.

View full company profile

Therapeutic Areas

DermatologyPulmonologyGastroenterologyImmunology

Other Moderate-to-Severe Atopic Dermatitis Drugs

DrugCompanyPhase
Zumilokibart (APG777)Apogee TherapeuticsPhase 2
ATI-1777Aclaris TherapeuticsPhase 2b